ArticleDiagnostic pathology2026
Construction of an integrated diagnostic-therapeutic model for prostate cancer using rapid multiplex immunohistochemistry.
Article in Diagnostic pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo explore the feasibility and clinical application value of constructing an integrated model for the diagnosis and treatment of prostate cancer based on rapid multiplex immunohistochemistry (RMI) combined with intraoperative frozen section examination (IFSE).
methodsA total of 50 patients with high suspicion of localized prostate cancer were prospectively enrolled at our hospital between January and November 2025. All patients underwent mpMRI/TRUS fusion‑guided transperineal targeted biopsy. Tissue specimens obtained during biopsy were processed for both IFSE and RMI. The RMI panel included antibodies against P504S, P63, 34βE12, and CK5/6. Patients with an intraoperative pathological diagnosis of prostate cancer proceeded directly to robot‑assisted laparoscopic radical prostatectomy (RARP). Those with negative intraoperative findings underwent systematic biopsy. The diagnostic performance of this model was evaluated using postoperative whole- mount histopathology or conventional pathology from systematic biopsy as the reference standard.
resultsThe overall pathological positivity rate in this study was 86.00% (43/50). Of these, 39 patients were intraoperatively diagnosed with prostate cancer by rapid pathology and subsequently underwent immediate RARP. IFSE alone diagnosed prostate cancer in 37 cases, with a diagnostic sensitivity of 94.87% (37/39). The concordance rate of Gleason score with postoperative pathology was 81.08%. IFSE combined with RMI diagnosed prostate cancer in all 39 cases, each later confirmed by postoperative pathology following RARP, yielding a diagnostic sensitivity of 100%. The Gleason score concordance rate improved to 97.44%. The false-negative rate was 5.13% for IFSE alone, compared to 0% for the combined IFSE and RMI approach. The mean time to obtain pathological results was 29.80 ± 3.92 minutes for IFSE alone, and 29.93 ± 2.35 minutes for IFSE combined with RMI, indicating no significant prolongation. All 39 patients who underwent immediate RARP had a mean hospital stay of 7.31 ± 1.41 days, with only one hospitalization episode per patient.
conclusionRMI effectively compensates for the limitations of IFSE alone. The combined application of IFSE and RMI within an integrated diagnostic–therapeutic model for prostate cancer significantly improves intraoperative diagnostic sensitivity and Gleason score accuracy without substantially extending waiting time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.